New stock news | DeMai Pharma submits application to Hong Kong Exchange, ranking first in revenue for skin prescription drugs among innovative drug companies in China.

According to the Wisdom Financial APP, as disclosed by the Hong Kong Stock Exchange on October 30, Delta Pharmaceutical Limited (referred to as Delta Pharmaceutical) has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. According to the Zhishi Consulting report, Delta Pharmaceutical's revenue from prescription skin drugs in 2024 ranks first among Chinese pharmaceutical companies focusing on innovative products and fifth among all Chinese pharmaceutical companies.